ATH 0.00% 0.3¢ alterity therapeutics limited

Ann: Meeting with US FDA provides development path for ATH434, page-7

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,640 Posts.
    lightbulb Created with Sketch. 143
    Wait ...what ? Am I understanding this correctly ?

    alterity now has to do a 1 year preclinical study prior to advancing discussions with FDA on endpoints for a p2 ?

    has the MSA route ( chosen to speed things up ) now backfired as no way to measure efficacy of p2 trial due to lack of data available so alterity now has to first produce said data ?

    please tell me I'm wrong
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.